Diversified Management Inc. Takes Position in AbbVie Inc. $ABBV

Key Points

• Diversified Management Inc. opened a new position of 5,938 shares (~$1.357M) in AbbVie during Q4, joining institutional owners who collectively hold about 70.23% of the company after large additions from firms like Wellington and Raymond James.
• Recent positive developments — including encouraging Phase 2 data for mirvetuximab (Elahere) and major deals such as AbbVie’s reported $650M upfront for RC148 plus a ~$715–$745M licensing agreement with Haisco — bolster the company’s oncology and pain pipelines and growth outlook.
• AbbVie reported revenue growth and set FY2026 guidance of EPS 14.37–14.57; the stock yields 3.3% (quarterly dividend $1.73) despite a high payout ratio (~293%), and company insiders have recently executed significant share sales.

Diversified Management Inc. acquired a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,938 shares of the company's stock, valued at approximately $1,357,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of ABBV. Wellington Management Group LLP lifted its stake in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Raymond James Financial Inc. lifted its stake in shares of AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares in the last quarter. Alliancebernstein L.P. lifted its stake in shares of AbbVie by 31.8% during the third quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company's stock worth $1,685,918,000 after purchasing an additional 1,758,657 shares in the last quarter. Amundi lifted its stake in shares of AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares in the last quarter. Finally, Danske Bank A S acquired a new position in shares of AbbVie during the third quarter worth about $279,609,000. Institutional investors and hedge funds own 70.23% of the company's stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late‑breaking Phase 2 data for mirvetuximab (Elahere) in platinum‑sensitive ovarian cancer and an exclusive pain‑therapy licensing deal reinforce AbbVie’s longer‑term oncology and pain pipelines, supporting growth expectations. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie paid a reported upfront to secure global rights to RC148, signaling management is investing in external oncology/R&D assets to bolster future revenue streams and diversify the pipeline. RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
• Positive Sentiment: AbbVie reached a large licensing agreement with Haisco (reported near $715–$745M), which monetizes or out‑licenses assets while extending geographic reach for certain pain therapies—positive for pipeline monetization and incremental revenue potential. Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
• Positive Sentiment: Early‑stage ABBV‑438 myeloma data continue to underscore AbbVie’s long‑term oncology ambitions; successful advancement would broaden oncology exposure beyond established franchises. AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
• Neutral Sentiment: AbbVie remains a dividend candidate for income investors and appears in recent roundups of high‑yield healthcare names, which supports income‑oriented demand even if growth questions persist. Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
• Neutral Sentiment: Commentary on AbbVie’s progress in the weight‑loss market highlights pipeline diversification but notes the company remains behind market leaders—an incremental positive but not an immediate revenue driver. Could AbbVie Crash Lilly's Weight‑Loss Party?
• Negative Sentiment: Evercore ISI slightly lowered its price target on ABBV (to $232 from $233) while keeping an Outperform rating—an incremental analyst headwind that can pressure intraday sentiment despite the small magnitude. Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Royal Bank Of Canada initiated coverage on AbbVie in a research note on Tuesday, February 24th. They set an "outperform" rating and a $260.00 price objective on the stock. Berenberg Bank set a $275.00 target price on AbbVie in a research report on Tuesday, January 20th. Cantor Fitzgerald dropped their target price on AbbVie from $250.00 to $240.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 8th. BMO Capital Markets reaffirmed an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and a consensus price target of $253.00.

AbbVie Stock Down 0.8%

Shares of NYSE ABBV opened at $208.58 on Thursday. The firm's 50-day moving average price is $219.49 and its two-hundred day moving average price is $223.78. AbbVie Inc. has a 52-week low of $168.54 and a 52-week high of $244.81. The stock has a market capitalization of $368.80 billion, a P/E ratio of 88.38, a P/E/G ratio of 0.75 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the business earned $2.16 earnings per share. AbbVie's revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie's dividend payout ratio (DPR) is 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.